Emphasising the European Union's Commitment to Cancer Research: A Helicopter View of the Seventh Framework Programme for Research and Technological Development
| Autor: | Maria Vidal, Karim Berkouk, Dominika Trzaska, Ruxandra Draghia-Akli, Jan-Willem van de Loo |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Cancer Research
Receptor ErbB-2 business.industry Breast Neoplasms Middle Aged Trastuzumab European Perspectives Antibodies Monoclonal Humanized Quality of life (healthcare) Oncology Cancer control Chemotherapy Adjuvant Survivorship curve Antineoplastic Combined Chemotherapy Protocols Cancer research Humans Medicine media_common.cataloged_instance Female European union business media_common |
| Zdroj: | The Oncologist. 17:e26-e32 |
| ISSN: | 1549-490X 1083-7159 |
| DOI: | 10.1634/theoncologist.2012-0327 |
| Popis: | A 53-year-old postmenopausal woman was found to have a new area of microcalcification at the 10 o'clock position of her right breast during a routine screening mammogram. Ultrasound-guided core biopsy revealed a grade 2 invasive ductal carcinoma, estrogen receptor (ER)+ (90%), progesterone receptor positive (20%), and human epidermal growth factor receptor (HER)-2+ (3+ by immunohistochemistry). A right breast lumpectomy and sentinel node biopsy were performed. The invasive tumor measured 0.7 cm, no lymphovascular space invasion was identified, surgical margins were uninvolved, and the sentinel lymph nodes were negative for tumor. She was evaluated postoperatively in the medical oncology clinic to discuss an adjuvant treatment strategy. The question for our colleagues is: should she be offered adjuvant chemotherapy and trastuzumab prior to adjuvant radiation and 5 years of hormonal therapy? |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text